Loading clinical trials...
Loading clinical trials...
Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy Compared to Capecitabine Monotherapy for TNBC With Residual Invasive Cancer After Neoadjuvant Chemotherapy.
Conditions
Interventions
Atezolizumab
Capecitabine
Locations
1
South Korea
Korea University, Guro hospital
Seoul, South Korea
Start Date
January 15, 2019
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2027
Last Updated
April 23, 2026
NCT06681064
NCT05005403
NCT06547840
NCT06649331
NCT07029399
NCT06134375
Lead Sponsor
National Cancer Center, Korea
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions